Clinical Evaluation of Skin Microbiome an Over-The-Counter (OTC) Drug for Atopic Dermatitis

Stopped early · Phase 1

Conditions studied: Atopic Dermatitis (AD)

In brief

This is a research study. The over-the-counter (OTC) drug for atopic dermatitis being tested is not approved as a treatment for the participants' atopic dermatitis condition. In participating in this study, the investigators will analyze the participants' skin microbiome, measure skin hydration and barrier function, and assess clinical improvements to help us understand the potential impact of the investigational OTC drug on atopic dermatitis and skin microbiome balance.

Key facts

Study ID

NCT07146971

Run by

Good Molecules, LLC

People needed

3

Starts

2025-08-14

Expected to finish

2026-05-12

Last updated by the study team

2026-05-27

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Previously diagnosed Atopic Dermatitis with active, visible flare-ups at time of screening
• Present dry/itchy skin patches on forearm, back of the hand, or posterior lower leg suitable for treatment assessment
• Evidence of inflammatory disease (documented diagnosis and current active symptoms)
• Stable skincare routine for 4 weeks prior to screening
• Subject willing to avoid conflicting topical treatments during study period
• Subject being used to applying topical treatments for atopic dermatitis
• General:
• Healthy subject apart from atopic dermatitis
• Subject having given free informed, written consent
• Subject willing to adhere to protocol and study procedures

You may not qualify if…

• Pregnant or nursing woman or woman planning to get pregnant during the study
• Recent (within 4 weeks) or current history of using atopic dermatitis biological drugs, such as dupilumab, lebrikizumab, nemolizumab, and tralokinumab
• Recent use of systemic antibiotics, steroids, or immunomodulators (within 4 weeks)
• Active skin infections unrelated to atopic dermatitis
• Severe dermatologic conditions requiring immediate medical intervention
• Use of topical or systemic treatment during previous weeks liable to interfere with assessment
• Subject having undergone surgery under general anaesthesia within the previous month
• Excessive exposure to sunlight or UV-rays within the previous month
• Subject having scars, tattoos on the forearms that would interfere with assessments
• Subject enrolled in another clinical trial during the study period and/or during the past 30 days

Where it is running

• Sequential Skin — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.